Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China,
China National Clinical Research Center for Neurological Diseases, Beijing, China,
Cerebrovasc Dis. 2023;52(4):460-470. doi: 10.1159/000527519. Epub 2023 Jan 30.
Elevated circulatory concentrations of YKL-40 have been reported in patients with ischemic stroke. This study further investigated the association of plasma YKL-40 concentrations at admission and short, long-term prognosis after ischemic stroke.
Based on a prospective, nationwide multicenter registry focusing consecutive patients of ischemic stroke and transient ischemic attack, plasma YKL-40 levels were detected by enzyme-linked immunosorbent assay at admission, and patients were stratified into percentile according to the plasma YKL-40 concentrations. The multivariate Cox or logistic regression model was used to investigate the association of YKL-40 concentration with death and functional outcomes at 3 months, 6 months, and 12 months after ischemic stroke, with potential confounders adjusted.
A total of 8,006 first-ever ischemic stroke patients, with the age of 61.7 ± 11.5, were included in this study. The mortality of 0-33%, 34-66%, 67-90%, and 91-100% groups at 12 months follow-up was 0.9%, 2.2%, 4.4%, and 9.4%, respectively (p < 0.0001), and the modified Rankin Scale 3-6 ratio was 6.8%, 10.5%, 15.7%, and 24.0%, respectively (p < 0.0001). In the multivariate regression, after adjusting for potential confounders, 91-100% group had higher risk of death (hazard ratio 2.99, 95% confidence interval 1.75-5.11)and modified Rankin Scale 3-6 (odds ratio 1.42, 95% confidence interval 1.08-1.88) at 12 months since onset of ischemic stroke compared to the 0-33% group.
The elevated YKL-40 at admission can potentially help predict death, functional prognosis after ischemic stroke, which may help further studies to explore the potential physiological and pathological mechanism including the effects of vulnerable plaque and collateral circulation.
已有研究报道,循环血中 YKL-40 浓度升高与缺血性脑卒中患者相关。本研究进一步探究了入院时的血浆 YKL-40 浓度与缺血性脑卒中短期和长期预后之间的关系。
本研究基于一项前瞻性的全国多中心登记研究,连续纳入缺血性卒中和短暂性脑缺血发作患者。入院时通过酶联免疫吸附试验检测血浆 YKL-40 水平,并根据血浆 YKL-40 浓度将患者分层为百分位数。采用多变量 Cox 或逻辑回归模型,调整潜在混杂因素后,研究 YKL-40 浓度与缺血性卒中发病后 3 个月、6 个月和 12 个月时的死亡和功能结局之间的关系。
本研究共纳入 8006 例首发缺血性卒中患者,年龄为 61.7±11.5 岁。12 个月随访时,0-33%、34-66%、67-90%和 91-100%组的死亡率分别为 0.9%、2.2%、4.4%和 9.4%(p<0.0001),改良 Rankin 量表 3-6 分的比例分别为 6.8%、10.5%、15.7%和 24.0%(p<0.0001)。在多变量回归中,调整潜在混杂因素后,91-100%组的死亡风险(风险比 2.99,95%置信区间 1.75-5.11)和缺血性卒中发病后 12 个月改良 Rankin 量表 3-6 分(比值比 1.42,95%置信区间 1.08-1.88)均高于 0-33%组。
入院时升高的 YKL-40 可能有助于预测缺血性卒中后的死亡和功能预后,这可能有助于进一步研究探索潜在的生理和病理机制,包括易损斑块和侧支循环的影响。